|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. 6. Contemplating what we have heard today, what do we think we know about what works and what does not, and what would be the most useful things that could/should happen next? GENERAL DISCUSSION and CHAIRMAN'S SUMMARY 5:30 ADJOURN Tuesday, February 11th 8:30 MEETING RESUMES ELEMENT 4: Discussion Panel, FDA and Industry Representatives 7. Current Legal/Regulatory Issues Around Development of Drugs and Vaccines for Emerging Infections
From the Food and Drug Administration: Elaine Esber Mark Goldberger Jeffrey Murray Stuart Nightingale From the Forum on Emerging Infections: Member Representatives from Industry 10:30 ADJOURN
|
||||||||||||||||
